{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-25-000050","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.097995+00:00","generated_at":"2026-05-28T04:08:08.595104+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4","bullets":["Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.","Ending cash balance $9.6M; Q4 generated positive cash flow of $0.8M.","Full-year cash burn $1.9M, a 67% improvement over prior year.","CEO cites U.S. market share gains, international expansion, and progress on new drug therapy labeling."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-25-000050","json":"https://secwatch.observer/filing/0001161697-25-000050.json","markdown":"https://secwatch.observer/filing/0001161697-25-000050.md","text":"https://secwatch.observer/filing/0001161697-25-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169725000050/0001161697-25-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169725000050/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:08:08.595104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}